Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic

Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) just unveiled an announcement.

On 12 January 2026, Radiopharm Theranostics announced it had increased its ownership stake in Radiopharm Ventures, LLC, its radiopharmaceutical joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%, signalling heightened confidence in the venture’s oncology pipeline. The move follows U.S. FDA IND clearance in July 2025 for Betabart (RV01), a B7H3‑targeting monoclonal antibody radiolabelled with lutetium-177, which is set to enter a Phase I dose-escalation therapeutic trial in multiple solid tumors with first patient dosing expected in the first quarter of 2026, in what is described as the first global clinical trial targeting B7H3 with a systemic radiopharmaceutical; alongside Betabart, two additional preclinical assets within Radiopharm Ventures have shown early positive data and are advancing toward final candidate selection in 2026, potentially strengthening Radiopharm’s position in the competitive cancer radiopharmaceuticals market and offering new avenues for growth for shareholders and partners.

The most recent analyst rating on (RADX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.

Spark’s Take on RADX Stock

According to Spark, TipRanks’ AI Analyst, RADX is a Neutral.

The score is held down primarily by sustained losses and persistent cash burn (negative operating and free cash flow), despite some revenue momentum. Technical signals are largely neutral with only mild positives, offering limited support. Valuation is difficult to assess due to negative earnings, and no dividend data is available.

To see Spark’s full report on RADX stock, click here.

More about Radiopharm Theranostics Limited Sponsored ADR

Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic use in areas of high unmet medical need. Listed on the ASX and Nasdaq, the company’s pipeline spans peptides, small molecules and monoclonal antibodies targeting a range of solid tumors, with one Phase 2 and four Phase 1 trials underway in indications including lung, breast and brain metastases.

Average Trading Volume: 762,217

Technical Sentiment Signal: Hold

Current Market Cap: $59.37M

For an in-depth examination of RADX stock, go to TipRanks’ Overview page.